HIGHLIGHTS
- who: Johanna Waidhauser from the Department of Hematology and Medical Oncology, University Medical Center Augsburg, Augsburg, Germany have published the paper: Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT, in the Journal: (JOURNAL)
- what: Patients provide informed consent authorizing the use of their personal information for research purposes before transplantation. Unlike other studies on the role of RUNX1 mutation on the outcome after alloSCT, this analysis has mainly included patients with de novo AML, which all . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.